-
公开(公告)号：WO2007056221A2
公开(公告)日：2007-05-18
申请号：PCT/US2006043096
申请日：2006-11-03
Applicant: VERTEX PHARMA , BINCH HAYLEY , MORTIMORE MICHAEL , DAVIS CHRIS , BOYALL DEAN , EVERITT SIMON , ROBINSON DANIEL , RAMAYA SHARN , FRAYSSE DAMIEN , STUDLEY JOHN , MILIER ANDREW , O'DONNELL MICHAEL , RUTHERFORD ALISTAIR , PINDER JOANNE
Inventor： BINCH HAYLEY , MORTIMORE MICHAEL , DAVIS CHRIS , BOYALL DEAN , EVERITT SIMON , ROBINSON DANIEL , RAMAYA SHARN , FRAYSSE DAMIEN , STUDLEY JOHN , MILIER ANDREW , O'DONNELL MICHAEL , RUTHERFORD ALISTAIR , PINDER JOANNE
IPC: A61K31/513
CPC classification number: C07D403/12 , C07D239/38 , C07D401/14 , C07D403/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention.
Abstract translation: 本发明涉及可用作蛋白激酶抑制剂的化合物。 本发明还提供包含这些化合物的药学上可接受的组合物和使用该化合物和组合物治疗各种疾病，病症和障碍的方法。 本发明还提供了制备本发明化合物的方法。
-
公开(公告)号：WO2007056163A3
公开(公告)日：2008-03-27
申请号：PCT/US2006042993
申请日：2006-11-03
Applicant: VERTEX PHARMA , BINCH HAYLEY , MORTIMORE MICHAEL , FRAYSSE DAMIEN , RUTHERFORD ALISTAIR
Inventor： BINCH HAYLEY , MORTIMORE MICHAEL , FRAYSSE DAMIEN , RUTHERFORD ALISTAIR
IPC: C07D403/14 , A61K31/4155 , C07D239/02
CPC classification number: C07D403/12 , C07D239/38 , C07D401/14 , C07D403/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
Abstract: The present invention relates to compounds useful as inhibitors of Aurora protein kinases . The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders . The invention also provides processes for preparing compounds of the invention.
Abstract translation: 本发明涉及可用作Aurora蛋白激酶抑制剂的化合物。 本发明还提供包含这些化合物的药学上可接受的组合物和使用该化合物和组合物治疗各种疾病，病症和障碍的方法。 本发明还提供了制备本发明化合物的方法。
-
公开(公告)号：WO2005085236A3
公开(公告)日：2005-10-20
申请号：PCT/US2005006540
申请日：2005-02-28
Applicant: VERTEX PHARMA , CHARRIER JEAN-DAMIEN , DURRANT STEVEN , MORTIMORE MICHAEL , O'DONNELL MICHAEL , RUTHERFORD ALISTAIR , RAMAYA SHARN , STUDLEY JOHN R , TRUDEAU MARTIN , LOOKER ADAM
Inventor： CHARRIER JEAN-DAMIEN , DURRANT STEVEN , MORTIMORE MICHAEL , O'DONNELL MICHAEL , RUTHERFORD ALISTAIR , RAMAYA SHARN , STUDLEY JOHN R , TRUDEAU MARTIN , LOOKER ADAM
IPC: A61K38/04 , A61K38/06 , C07D207/16 , C07D209/52 , C07D401/12 , C07D401/14 , C07D405/12 , C07D417/06 , C07D417/12 , C07K5/02 , C07K5/04 , A61K31/401 , A61K31/4025 , A61K31/403 , A61K31/443 , A61P37/00
CPC classification number: C07D405/12 , A61K38/06 , C07D207/16 , C07D209/52 , C07D401/12 , C07D401/14 , C07D417/06 , C07D417/12 , C07K5/0202
Abstract: The present invention provides a compound of formula (I): wherein the variables are as defined herein. The present invention also provides processes for preparing the compounds of formula (I), and intermediates thereof, pharmaceutical compositions comprising those compounds, and methods of using the compounds and compositions.
Abstract translation: 本发明提供式（I）的化合物：其中变量如本文所定义。 本发明还提供制备式（I）化合物及其中间体，包含那些化合物的药物组合物的方法，以及使用该化合物和组合物的方法。
-
公开(公告)号：EP1951715A4
公开(公告)日：2011-11-09
申请号：EP06827465
申请日：2006-11-03
Applicant: VERTEX PHARMA
Inventor： BINCH HAYLEY , MORTIMORE MICHAEL , FRAYSSE DAMIEN , RUTHERFORD ALISTAIR
IPC: C07D401/14 , A61K31/505 , C07D403/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
CPC classification number: C07D403/12 , C07D239/38 , C07D401/14 , C07D403/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
-
公开(公告)号：EP1954277A4
公开(公告)日：2011-11-09
申请号：EP06836938
申请日：2006-11-03
Applicant: VERTEX PHARMA
Inventor： BINCH HAYLEY , MORTIMORE MICHAEL , DAVIS CHRIS , BOYALL DEAN , EVERITT SIMON , ROBINSON DANIEL , RAMAYA SHARN , FRAYSSE DAMIEN , STUDLEY JOHN , MILIER ANDREW , O'DONNELL MICHAEL , RUTHERFORD ALISTAIR , PINDER JOANNE
IPC: A61K31/505 , C07D239/02 , C07D401/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
CPC classification number: C07D403/12 , C07D239/38 , C07D401/14 , C07D403/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
-
Patent Agency Ranking
公开(公告)号：AU2019211485B2
公开(公告)日：2025-01-23
申请号：AU2019211485
申请日：2019-01-28
Applicant: MERCK PATENT GMBH , VERTEX PHARMA
Inventor： BAYLY ANDREW , BLEICH MATTHEW , CHARRIER JEAN-DAMIEN , DODD JAMES , DURRANT STEVEN , ENO MEREDITH SUZANNE , ETXEBARRIA I JARDI GORKA , EVERITT SIMON , FRAYSSE DAMIEN , KELLY SHAZIA , KNEGTEL RONALD , MOCHALKIN IGOR , MORTIMORE MICHAEL , NORTH KIRI , PORICHIS FILIPPOS , PULLIN ROBERT , RUTHERFORD ALISTAIR , STORCK PIERRE-HENRI , TWIN HEATHER CLARE , XIAO YUFANG
IPC: A61K31/495 , A61K31/505 , A61K31/519 , C07D487/00 , C07D487/02 , C07D487/04
Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
-
公开(公告)号：SI3354650T1
公开(公告)日：2022-06-30
申请号：SI200932162
申请日：2009-12-18
Applicant: VERTEX PHARMA
Inventor： KAY DAVID , CHARRIER JEAN-DAMIEN , DURRANT STEVEN , KNEGTEL RONALD , MACCORMICK SOMHAIRLE , MORTIMORE MICHAEL , O'DONNELL MICHAEL , PINDER JOANNE , RUTHERFORD ALISTAIR , VIRANI ANISA NIZARALI , YOUNG STEPHEN , REAPER PHILIP MICHAEL
IPC: C07D413/00 , A61K31/00 , A61P35/00 , C07D401/00 , C07D403/00 , C07D409/00 , C07D417/00 , C07D471/00
-
公开(公告)号：AU2018201363C1
公开(公告)日：2020-06-18
申请号：AU2018201363
申请日：2018-02-26
Applicant: VERTEX PHARMA
Inventor： CHARRIER JEAN-DAMIEN , DURRANT STEVEN , KAY DAVID , KNEGTEL RONALD , MACCORMICK SOMHAIRLE , MORTIMORE MICHAEL , O'DONNELL MICHAEL , PINDER JOANNE , RUTHERFORD ALISTAIR , YOUNG STEPHEN , REAPER PHILIP MICHAEL , VIRANI ANISA NIZARALI
IPC: C07D413/04 , A61K31/497 , A61P35/00 , C07D401/14 , C07D403/12 , C07D409/14 , C07D413/12 , C07D417/04 , C07D417/12 , C07D471/04
Abstract: Abstract The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; me thods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermedia tes fo r the prepara tion of the com pound s of this inve ntion; an d method s of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the com parative evaluation of n ew kin ase inhibitors. The compo un ds of this invention have formula (I):whereir the variables are as defined herein
-
公开(公告)号：DK2376485T3
公开(公告)日：2018-03-12
申请号：DK09798991
申请日：2009-12-18
Applicant: VERTEX PHARMA
Inventor： CHARRIER JEAN-DAMIEN , DURRANT STEVEN , KAY DAVID , KNEGTEL RONALD , MACCORMICK SOMHAIRLE , MORTIMORE MICHAEL , O'DONNELL MICHAEL , PINDER JOANNE , RUTHERFORD ALISTAIR , VIRANI ANISA NIZARALI , YOUNG STEPHEN , REAPER PHILIP MICHAEL
IPC: C07D413/04 , A61K31/497 , A61P35/00 , C07D401/14 , C07D403/12 , C07D409/14 , C07D413/12 , C07D417/04 , C07D417/12 , C07D471/04
-
公开(公告)号：AU2016222396A1
公开(公告)日：2016-10-13
申请号：AU2016222396
申请日：2016-08-31
Applicant: VERTEX PHARMA
Inventor： CHARRIER JEAN-DAMIEN , DURRANT STEVEN , KAY DAVID , KNEGTEL RONALD , MACCORMICK SOMHAIRLE , MORTIMORE MICHAEL , O'DONNELL MICHAEL , PINDER JOANNE , RUTHERFORD ALISTAIR , YOUNG STEPHEN , REAPER PHILIP MICHAEL , VIRANI ANISA NIZARALI
IPC: C07D413/04 , A61K31/497 , A61P35/00 , C07D401/14 , C07D403/12 , C07D409/14 , C07D413/12 , C07D417/04 , C07D417/12 , C07D471/04
Abstract: The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula (I): wherein the variables are as defined herein. N (L)n-R'
-
-
-
-
-
-
-
-
-
Search Results
97
records
(took 0.029 seconds)
